02:00 PM EDT, 05/27/2025 (MT Newswires) -- NeuroPace ( NPCE ) said Tuesday that initial one-year results from its study evaluating the RNS system in idiopathic generalized epilepsy failed to achieve statistical significance for its primary effectiveness target in the full trial population.

The stock slumped 30% as intraday volume topped 1.18 million shares versus the daily average of almost 247,000.

Savara (SVRA) received a refusal-to-file letter from the US Food and Drug Administration for the biologics license application of Molbreevi to treat autoimmune pulmonary alveolar proteinosis, a rare lung disease.

The shares tumbled 29% as volume topped 16.1 million versus the daily average of almost 1.02 million.

PDD Holdings ( PDD ) shares slumped 15% intraday after the company reported Q1 non-GAAP earnings and sales that missed analysts' expectations.

Volume topped 42.2 million versus the daily average of 10 million.

Price: 12.30, Change: -5.39, Percent Change: -30.46